HtmlToText
home learn about guide for the newly diagnosed brain tumor symptoms noteworthy treatments brain tumor news fundraising for research! frequently asked questions common brain tumor terms dictionary survivor stories dipg / brainstem tissue donations gliadel ® wafer optune™ (novocure novottf-100a ® ) temodar ® tocagen toca 511 ® / toca fc ® vaccines & immunotherapy find a treatment find clinical trials new trials listings treatments list virtual trial what is it? join post an update map of participants interact newsletter contact us video library unsubscribe resources copayment assistance program drug discount card brain tumor centers online support groups social security disability and brain tumors links books brain tumor organizations resources for kids young adult survivor resources support groups college scholarships memorials prayer list about us musella foundation research grants recent additions to website privacy policy site map our sponsors awards website design make a donation financials donations visa/ mastercard / discover / amex check stocks / planned giving / wills special research funds dipgc immunotherapy research fund oligo fund rosenbaum gbm research fund memorial and in honor donations a-e bender, sharon bundick, john a. cannon, paula card, andy chakravorty, satya coney, mark cooper, francis xavier dickens, brian eichinger, shawn erickson, priscilla j. f-m friesenhahn, cynthia gayle gomory, stephen henry hansen, muriel elyned kralik, patricia lisciandra, filippa molloy, james mosic, ronald moss, robert musella, ken n-r nelson, mark thomas o'brien, shannon parks, laura marie peters, meredith dale ride the divide robinson, laurie jean rogat, aaron douglas rose, catherine roth, rona s-z salkowski, mark s. sfeir, nadine stanziale, marie stott, michael walker, ruth wetzel, christi zeilstra, steve zimmerman, gayle h officers al musella, dpm president mitchell siegel vice president steven ruttgeizer treasurer neal houslanger, dpm secretary medical advisory board keith black md cedars sinai medical center nicholas a. blondin, md st. vincent's brain tumor center john a. boockvar, md lenox hill hospital arno fried, md hackensack university medical center henry friedman, md preston robert tisch brain tumor center at duke isabelle m germano, md, mba mount sinai new york, ny roberta hayes, ph.d. new york, ny gil lederman, md radiosurgery new york mark levin, md new york, ny linda liau, md, ph.d. ucla medical center hideho okada md, phd ucsf, ca michael schulder, md northwell health, ny virginia stark- vance, m.d. dallas,tx fort worth, tx lee eric tessler, md long island brain tumor center stephen thompson, md hackensack university medical center katherine e. warren, md bethesda, maryland paul m. zeltzer md encino, ca our privacy policy has changed click here to view the new policy sponsored by please click on the above banner for more details introduction the musella foundation for brain tumor research & information, inc is a 501(c)3 nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. search: this site was last updated on: 08/01/2018 10:58 am . click here to see what was added! newly diagnosed brain tumor (brain cancer) patients checklist for newly diagnosed brain tumor patients. start here! (updated 5/29/18) recurrent glioblastoma treated with recombinant poliovirus (updated 6/26/2018) interim results for dcvax trial - outstanding results for newly diagnosed glioblastomas! (5/29/18) note: if you are going to have a brain tumor surgery, ask about this treatment! brain tumor awareness month 2018 webinar series are now online! (5/29/18) al musella's thoughts on what he would do if he had a newly diagnosed gbm. (8/14/17) (11/21/17) high compliance with optune linked to greatest survival benefit for glioblastoma 29% 5 year survival in high compliance group compared to 4.5% in control group. (9/27/17) amazing increase in survival for newly diagnosed gbm by adding ccnu survival for newly diagnosed mgmt methylated gbm patients was 46.9 months! (9/27/17) long term outcomes reported from optune trial more than doubles chances of being alive at 5 years for gbm patients! nccn updated cns cancer treatment guidelines to include optune (7/25/16) 11/26/16 highlights of 2016 society for neuro oncology annual meeting 8/31/17 "treatment options for glioblastoma and other gliomas" ben williams' aug 2017 update - an excellent report on all treatments for glioblastomas - a must read! maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma this may become the new standard of care for glioblastoma multiforme! (added 12/15/15) brain tumor guide for the newly diagnosed- new (12/1/2016) 10th edition! a free 123 page online book covering what you need to know now! 8/24/15 nw bio confirms phase iii trial of dcvax®-l for gbm brain cancer is ongoing patients in trial continuing to be treated per protocol, including in germany 11/15/14 novocure announces the ef-14 phase iii clinical trial of tumor treating fields in patients with newly diagnosed glioblastoma has been terminated at the interim analysis due to early success 10/29/14 supplement to "seminars in oncology" devoted to novottf-100a. this is a set of 4 research papers and an introduction. this is the publication of the registry data mentioned below. it goes into more details on the analysis of how the treatment works in patients and patterns of response. it shows that in about 50% o the patients who respond, the first mri looks worse, and it takes about 5 months for the mris to start to look better - so be aware and do not give up too soon. germany oks northwest bio brain cancer drug great news! dc-vax can now be sold in germany. immunocellular therapeutics phase ii study demonstrates that glioblastoma patients live longer without disease progression when treated with ict-107 - results not as good as we hoped it would be, but it is still too early to tell vaccine update: 50 percent of patients in cedars-sinai brain cancer study alive after five years survival in patients with glioblastoma receiving valganciclovir this is an update to: new theory on cause - and way to treat glioblastomas: click here and here and here novocure ttf-100a device information note: the video below is old but explains the concept. the treatment is now fda approved. for details click here click here for other important brain tumor videos! important news: subscribe to our free brain tumor blast super selective intra arterial infusion a new way to get treatments to where they are needed! treatment options for glioblastoma multifore by ben williams, phd (update 2/9/2013) delayed response and survival from novottf-100a in recurrent gbm . a case report of a patient from the trial for recurrent gbms, who has been on the device and doing well for 6 years. of note is his initial mri after sterting the device looked worse. this shows that the device takes time to work and some people have been stopping too soon. adding avastin to radiation and chemotherapy extended the time people with a glioblastoma lived without their disease worsening - but did not extend overal survival ict-107 vaccine trial reports excellent results and it was funded by the musella foundation! [note: this shows how important your donations are!] phase 2 study of dose-intense temozolomide in recurrent glioblastoma unfortunately - shows that trying a different dose-intensive schedule of temodar after failing the standard schedule did not help much new trial opens - with new concept in treating brain tumors: interlaced therapy! brain tumor patient`s success story helps gain support for new treatment! novottf-100a versus physician's choice chemotherapy in recurrent glioblastom: a randomized phase 3 trial of a novel treatment modality . this is the report on the large trial that let to the fda approval of the novo
Informations Whois
Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;
Domain Name: VIRTUALTRIALS.COM
Registry Domain ID: 1089633_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.wildwestdomains.com
Registrar URL: http://www.wildwestdomains.com
Updated Date: 2017-12-11T18:28:39Z
Creation Date: 1996-10-25T04:00:00Z
Registry Expiry Date: 2019-01-16T04:59:59Z
Registrar: Wild West Domains, LLC
Registrar IANA ID: 440
Registrar Abuse Contact Email: abuse@wildwestdomains.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS2.A1WEBS.COM
Name Server: PDNS01.DOMAINCONTROL.COM
Name Server: PDNS02.DOMAINCONTROL.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-05-25T16:24:49Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR Wild West Domains, LLC
SERVERS
SERVER com.whois-servers.net
ARGS domain =virtualtrials.com
PORT 43
TYPE domain
RegrInfo
DOMAIN
NAME virtualtrials.com
CHANGED 2017-12-11
CREATED 1996-10-25
STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientRenewProhibited https://icann.org/epp#clientRenewProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
NSERVER
NS2.A1WEBS.COM 72.89.75.163
PDNS01.DOMAINCONTROL.COM 216.69.185.50
PDNS02.DOMAINCONTROL.COM 208.109.255.50
REGISTERED yes
Go to top
virtualtrials.com rapport :
Visitez le site